The best I can say about Hong Kong is that it's someone who wants the option to buy shares later this year at the price he has been paying, for whatever unknown reason.

IMO the probability of a buyout before Phase II results is very low.

And any blockbuster stock boosting results from a Phase II are a long way off.  The timeline is already slipping.  I expect more of the same.

ZEN-3694 in combination with enzalutamide in mCRPC patients

MD&A Dec 23 2022

"....Data from this trial is expected to readout in late calendar 2024 based on study accrual...."

MD&A Apr 6 2023

"....Interim data from this trial is expected to readout in late 2024 or early 2025 based on study accrual...."